Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivoryon Therapeutics N.V., a clinical stage biotechnology company, has announced the successful completion of its share capital reduction from EUR 1.00 to EUR 0.01 per share, a move aimed at enhancing the company’s financial agility. This strategic step, approved by shareholders and unopposed in the creditor opposition procedure, is expected to facilitate new financing, M&A activities, and the granting of equity awards. The reduction amount has been transferred to the company’s distributable reserves, with no change in the total number of shares issued.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.